Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
Biofrontera AG (NASDAQ: BFRA) will announce its financial results for the first half of 2021 on August 19, 2021. A conference call for shareholders and investors will take place on August 20, 2021, with sessions in German at 10:00 am CEST and in English at 2:00 pm CEST. Dial-in details are provided for both sessions. Biofrontera specializes in dermatological drugs, including Ameluz®, which treats skin cancers, and Xepi®, which is for impetigo. The company is notable for being the first German founder-led pharmaceutical company to achieve centralized approvals in Europe and the US.
- Biofrontera has achieved centralized European and US approvals for its in-house developed drug.
- The company has a solid product portfolio, including Ameluz® and Xepi®.
- None.
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021.
Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times:
In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)
Dial-in number Germany: +49 69201744220
Conference code: 63828444#
In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 78540812#
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
-End-
Biofrontera AG
Pamela Keck, Head of Investor Relations
ir@biofrontera.com
+49-214-87632-0
About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
FAQ
When will Biofrontera AG release its financial results for the first half of 2021?
What is the schedule for Biofrontera AG's conference calls?
What products does Biofrontera AG focus on?
